BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC
Bio-Techne (NASDAQ: TECH) has announced a new distribution agreement with Thermo Fisher Scientific, effective May 1, 2024. This strategic partnership will see Thermo Fisher distributing Bio-Techne's innovative products across Europe, enhancing support for researchers and accelerating scientific discoveries. The collaboration aims to empower scientists in areas such as cell and gene therapy, immunology, and neuroscience, ultimately advancing healthcare outcomes. Thermo Fisher's dedication to fostering innovation and collaboration within the scientific community is highlighted through this partnership.
Bio-Techne partners with Thermo Fisher Scientific to expand its product reach in Europe.
The collaboration aims to accelerate scientific discoveries in various fields such as cell and gene therapy and immunology.
Thermo Fisher reinforces its commitment to providing customers with cutting-edge technologies and expertise.
Potential risks associated with the distribution agreement impacting Bio-Techne's revenue or market presence.
Bio-Techne's strategic distribution agreement with Thermo Fisher Scientific leverages Thermo Fisher's strong distribution network across Europe, potentially enhancing Bio-Techne's market penetration and reach. It opens new channels for Bio-Techne's antibodies, proteins and other bioactive reagents, which could increase the company's sales volume in the strategically important European market.
To assess the potential financial impact, consider Thermo Fisher's vast infrastructure and customer base. The synergy between Thermo Fisher's distribution capabilities and Bio-Techne's product range could result in increased market share and revenue for Bio-Techne. Moreover, this partnership may streamline operations and reduce distribution costs for Bio-Techne, potentially improving profit margins.
It's important for investors to monitor the implementation of this agreement and any subsequent financial disclosures or sales figures that indicate the partnership's success. Investors should be aware that while the deal may be promising, the actual impact on Bio-Techne's financials will only become clear with time and execution.
The collaboration between Bio-Techne and Thermo Fisher is reflective of the current trend in the life sciences industry towards consolidation and strategic partnerships. By combining Bio-Techne's innovative product portfolio with Thermo Fisher's established presence in Europe, the partnership is expected to accelerate scientific research and could lead to advancements in healthcare.
As an industry expert, I note that the distribution agreement could facilitate the adoption of cutting-edge research tools, which is vital for maintaining a competitive edge. Access to high-quality reagents and tools is a key factor for research institutions when considering advancements in cell and gene therapy, immunology and neuroscience.
The long-term implications for the industry include potential acceleration of healthcare breakthroughs due to improved research capabilities. Moreover, enhanced support for researchers through a more extensive distribution network could also lead to faster commercialization of new therapies.
This partnership marks an important collaboration between two industry leaders in the fields of scientific research, diagnostics, and biotechnology. Under this agreement, Thermo Fisher, through the European arm of its Fisher Scientific Channel, will distribute Bio-Techne's extensive portfolio of innovative products, including antibodies, proteins, Immunoassay kits, reagents and enzymes to laboratories and research institutions across
"We are excited to partner with Thermo Fisher to expand the reach of our products and services throughout
Bio-Techne's state-of-the-art products are designed to accelerate research and improve outcomes in areas including cell and gene therapy, immunology, neuroscience, and more. With this collaboration, Thermo Fisher reinforces its commitment to providing customers with access to the latest technologies and expertise, ultimately advancing scientific knowledge and improving human health.
"We are thrilled to forge this partnership with Bio-Techne, a company renowned for its pioneering advancements in the life sciences industry," said Claire Wallace, President Research and Safety Market,
"Thermo Fisher is an ideal partner to accelerate our already strong presence in
This distribution agreement underscores Thermo Fisher's dedication to fostering innovation and collaboration within the scientific community. Through strategic partnerships with leading companies like Bio-Techne, Thermo Fisher continues to strengthen its position as a trusted partner for researchers and laboratories across
For more information about Bio-Techne and its range of products and services, visit our Website.
For more information about the Fisher Scientific Channel in
About Bio-Techne:
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over
Contact:
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
Fisher Scientific Europe is a part of Thermo Fisher Scientific.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than
Contact
Lynn Bannatyne, Director, EMEA Communications
emeacommunications@thermofisher.com
+44 7534696216
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-new-distribution-agreement-with-thermo-fisher-scientific-302128389.html
SOURCE Bio-Techne Corporation
FAQ
What is the new distribution agreement announced by Bio-Techne?
The new distribution agreement is with Thermo Fisher Scientific, effective May 1, 2024, to distribute Bio-Techne's products in Europe.
What are the benefits of the partnership between Bio-Techne and Thermo Fisher?
The partnership aims to accelerate scientific discoveries in areas like cell and gene therapy and enhance support for researchers in Europe.
Who are the key executives mentioned in the press release?
The key executives mentioned are Kim Kelderman, Claire Wallace, and Dr. Peter Schüßler.
How can I learn more about Bio-Techne and Thermo Fisher Scientific?
You can visit Bio-Techne's website or the Fisher Scientific Channel website for more information.
